Announcements Trials
Browse Landscape

Status

Completed 272Terminated 79Unknown 37Active not recruiting 19Recruiting 17Withdrawn 9Not yet recruiting 3Approved for marketing 2Suspended 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Afatinib 33-Iodobenzylguanidine 3niraparib 2lenvatinib 2ibrutinib 2gallium 68 PSMA-11 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Gefitinib 2Fluorouracil 2Capecitabine 2Amifampridine 2Abiraterone Acetate 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × Sunitinib × Clear all
NCT00094029 2012-03-09

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Pfizer

Approved for marketing
Gastrointestinal

Gastrointestinal Neoplasms

NCT00130897 2012-03-09

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Pfizer

Approved for marketing
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡